Evidence map›Paper›PMID 30319917›Full record

ArticleBiomedical optics express2018

Use of Raman spectroscopy to screen diabetes mellitus with machine learning tools.

Edgar Guevara, Juan Carlos Torres-Galván, Miguel G Ramírez-Elías, Claudia Luevano-Contreras, Francisco Javier González

Open access · goldAbstract read
In one paragraph

Article in Biomedical optics express, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
11.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 118 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Edgar GuevaraCONACYT-Universidad Autónoma de San Luis Potosí, Mexico.
Juan Carlos Torres-GalvánTerahertz Science and Technology Center (C2T2) and Science and Technology National Lab (LANCyTT), Universidad Autónoma de San Luis Potosí, Mexico.
Miguel G Ramírez-ElíasFacultad de Ciencias, Universidad Autónoma de San Luis Potosí, Mexico.
Claudia Luevano-ContrerasDepartment of Medical Sciences, University of Guanajuato, Leon, Mexico.
Francisco Javier GonzálezTerahertz Science and Technology Center (C2T2) and Science and Technology National Lab (LANCyTT), Universidad Autónoma de San Luis Potosí, Mexico.
Autonomous University of San Luis Potosí · MXUniversidad de Guanajuato · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Type 2 diabetes mellitus (DM2) is one of the most widely prevalent diseases worldwide and is currently screened by invasive techniques based on enzymatic assays that measure plasma glucose concentration in a laboratory setting. A promising plan of action for screening DM2 is to identify molecular signatures in a non-invasive fashion. This work describes the application of portable Raman spectroscopy coupled with several supervised machine-learning techniques, to discern between diabetic patients and healthy controls (Ctrl), with a high degree of accuracy. Using artificial neural networks (ANN), we accurately discriminated between DM2 and Ctrl groups with 88.9-90.9% accuracy, depending on the sampling site. In order to compare the ANN performance to more traditional methods used in spectroscopy, principal component analysis (PCA) was carried out. A subset of features from PCA was used to generate a support vector machine (SVM) model, albeit with decreased accuracy (76.0-82.5%). The 10-fold cross-validation model was performed to validate both classifiers. This technique is relatively low-cost, harmless, simple and comfortable for the patient, yielding rapid diagnosis. Furthermore, the performance of the ANN-based method was better than the typical performance of the invasive measurement of capillary blood glucose. These characteristics make our method a promising screening tool for identifying DM2 in a non-invasive and automated fashion.

Indexed as

(070.5010) Pattern recognition(170.4580) Optical diagnostics for medicine(170.5660) Raman spectroscopy

Identifiers

PMID30319917
PMCPMC6179393
OpenAlexW2892600563

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.